Appointments

Submit a Form

Questions

Submit a Form

Cancer Answer Line:
866.223.8100

M-F 8 a.m. - 4:30 p.m. ET

Expand Content

View Cancer Clinical Trials

HLM 1908   |   CC847
A Phase 1 Study of Sequential Idarubicin + Cytarabine, Followed by Lenalidomide, in Patients with Myelodysplastic Syndrome (RAEB-2) or With Previously Untreated Acute Myeloid Leukemia

Disease(s)
Leukemia, Acute Myeloid (AML)
Myelodysplastic Syndrome (MDS)
Hospital(s)
Main Campus
Phase(s)
Phase 1
Stage(s)
N/A
Type(s)
Therapeutic
Drug(s)
Cytarabine
Idarubicin
Lenalidomide (Revlimid)

Contact Information
Cancer Answer Line

866.223.8100

8:00 am - 4:30 pm, Monday - Friday


Description
  1. Primary Objective
    • To determine the maximum tolerated dose of lenalidomide following cytarabine and idarubicin as induction chemotherapy.
  2. Secondary Objectives
    • To determine the clinical efficacy of lenalidomide following idarubicin and cytarabine as induction therapy and as consolidation therapy.

Inclusion Criteria
  1. Understand and voluntarily sign an informed consent form.
  2. Age ≥ 18 years at the time of signing the informed consent form.
  3. Able to adhere to the study visit schedule and other protocol requirements.
  4. Disease-specific criteria
    • Previously untreated Acute Myeloid Leukemia (AML), associated with monosomy 5 or segmental deletion involving 5q31, either alone or with additional cytogenetic abnormalities.
    • Previously untreated AML (age ≥ 60 years)
    • Myelodysplastic Syndrome, Refractory Anemia with Excess Blasts-2 (MDS, RAEB-2, 10-19% blasts in the bone marrow) associated with monosomy 5 or segmental deletion involving 5q31, either alone or with additional cytogenetic abnormalities
  5. ECOG performance status of ≤ 2 at study entry (see Appendix C).
  6. Left ventricular ejection fraction (LVEF) ≥ 50%
  7. Laboratory test results within these ranges:
    • Serum creatinine ≤ 2.0 mg/dL
    • Total bilirubin ≤ 1.5 mg/dL (Gilbert's syndrome excluded)
    • AST (SGOT) and ALT (SGPT) ≤ 2 x ULN.
  8. Disease free of prior malignancies for ≥ 2 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma “insitu” of the cervix or breast.
  9. Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days prior to and again within 24 hours of starting lenalidomide. For FCBP who have a medical need to proceed with therapy immediately, the pregnancy test that would normally be done 10-14 days prior to initiation of lenalidomide may be done as late as 7 days prior to initiation of lenalidomide. Both this test and the pregnancy testing done within 24 hours prior to initiation of lenalidomide must be negative. FCBP must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex* condom during sexual contact with a FCBP even if they have had a successful vasectomy. All patients must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure. See Appendix A: Risks of Fetal Exposure, Pregnancy Testing Guidelines and Acceptable Birth Control Methods, AND also Appendix B: Education and Counseling Guidance Document. *For patients who have latex allergies or whose partner(s) have latex allergies, alternatives will be discussed.
  10. Must be able to swallow capsules and no evidence of GI tract abnormality that would alter absorption of oral medications.
  11. Understand and voluntarily sign an informed consent form.
  12. Life expectancy > 3 months.

Exclusion Criteria
  1. Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.
  2. Pregnant or breast feeding females. (Lactating females must agree not to breast feed while taking lenalidomide).
  3. Unwilling or unable to participate with FDA mandated birth control and pregnancy guidelines.
  4. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
  5. Use of any other experimental drug or therapy within 28 days of baseline.
  6. Known hypersensitivity to thalidomide.
  7. The development of erythema nodosum, if characterized by a desquamating rash, while taking thalidomide or similar drugs.
  8. Any prior use of lenalidomide.
  9. AML with cytogenetics including t(15;17), t(8;21), or inv(16).
  10. WBC count ≥ 50,000 on hydroxyurea therapy.
  11. Previous history of induction chemotherapy for AML or allogeneic stem cell transplant.
  12. Predicted inability to tolerate standard induction chemotherapy with idarubicin and cytarabine.
  13. History of spontaneous thromboembolic event requiring use of anticoagulation with warfarin (coumadin) or low molecular-weight heparin within 3 years.
  14. Known positive for HIV or infectious hepatitis, type A, B or C.

Cancer Answers & Appointments

Speak with a cancer nurse specialist for appointment assistance and for answers to your questions about cancer locally at 216.444.7923 or toll-free 1.866.223.8100.

Monday through Friday from 8 a.m. – 4:30 p.m. (ET).

Referrals

Resources for medical professionals

  • Outpatient appointment referrals: 216.444.7923 or 866.223.8100
  • Inpatient hospital transfers: 800.553.5056
  • Referring Physician Concierge: 216.444.6196 or 216.312.4910.

Clinical Trials

Search available cancer clinical trials by disease, hospital, phase or number.

This information is provided by Cleveland Clinic and is not intended to replace the medical advice of your doctor or health care provider. Please consult your health care provider for advice about a specific medical condition.

© Copyright 2014 Cleveland Clinic. All rights reserved.